Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers musculoskeletal solutions, including spine products, such as traditional fusion implants, and treatment options for motion preservation technologies, and interventional solutions to treat vertebral compression fractures; orthopedic trauma solutions, which includes fracture plating, intramedullary nailing, and regenerative biologic products; hip and knee joint solutions, including modular hip stems and acetabular cups for total hip arthroplasty, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants; and neuromonitoring services, which provides onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company also offers enabling technologies, such as imaging, navigation, and robotics (INR) solutions for assisted surgery, which includes the ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures with screw and interbody spacer placement applications; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative, image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cell, tissue, and cellular and tissue-based products. The company sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Globus Medical Inc. Class A

Stifel Nicolaus analyst Thomas Stephan maintained a Hold rating on Globus Medical on May 8 and set a price target of $95.00. The company’s shares c...

Stifel Nicolaus Reaffirms Their Hold Rating on Globus Medical (GMED)

Globus Medical (($GMED)) has held its Q1 earnings call. Read on for the main highlights of the call. Globus Medical’s latest earnings call struck a...

Globus Medical Earnings Call Signals Profitable Momentum

Piper Sandler Sticks to Their Buy Rating for Globus Medical (GMED)

Canaccord Genuity analyst Caitlin Cronin reiterated a Buy rating on Globus Medical today and set a price target of $115.00. According to TipRanks, ...

Current Quarter	$1.12	Next Quarter	$1.16
Current Year	$4.74	Next Year	$5.06
QoQ Growth	+3.6%	YoY Growth	+6.8%
3Y EPS CAGR	+28.2%	Target Price	$111.08
Consensus	Buy	Upside	+30.5%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GMED	$85.10	+0.34%	1.88M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GMED	$85.10	+0.3%	1.88M
3
4
5
6

GMED

GMED

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Globus Medical Inc. Class A Data in Excel

Get Globus Medical Inc. Class A Data in Excel